BCDA BioCardia: Bathi resik saben saham (EPS TTM)

BioCardia, Inc. (BCDA) management is focused on developing innovative cell therapy to combat heart failure. Net income per share TTM reflects current trends, with the value stabilizing at -0.76. Business success is based on the effectiveness of the CardiAMP system, however, a shallow economic moat and dependence on regulators create significant development risks.

BCDA Bathi saben saham sajroning taun lumaku BioCardia Inc (04.07.2022 - 10.11.2026)

Rincian metrik lan analitis perusahaan BioCardia Inc. (BCDA)

- rega saham lan target rega konsensus:

Rega saham BioCardia, Inc.|BCDA - Target konsensus

- data kapitalisasi saham perusahaan:

Kapitalisasi pasar BioCardia, Inc.|BCDA - Nilai Perusahaan

- rincian valuasi buku bisnis:

Aset Bersih saben Siji Saham BioCardia|BCDA - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku biocardia.com|BCDA - Total Aset Bisnis

- data tingkat utang lan likuiditas finansial:

Total Utang marang Modal BioCardia, Inc.|BCDA - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang modal BioCardia, Inc|BCDA - Gunggung utang perusahaan|Utang marang nilai buku BioCardia, Inc.|BCDA - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan BioCardia|Likuiditas cepet biocardia.com

- data bathi lan kelipatan valuasi:

BCDA - Bathi perusahaan|Proyeksi bathi mangsa ngarep BioCardia, Inc.|BCDA - Koefisien rega marang bathi|Prakiraan rega marang bathi BioCardia|BCDA - Kapitalisasi marang bathi resik kanthi nimbang wutah|Pangali EV/EBITDA BioCardia, Inc.|BCDA - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) BioCardia|BCDA - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan biocardia.com|BCDA - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep BioCardia, Inc.

Analisis kabeh metrik perusahaan:BioCardia, Inc. - BCDA

As a manager, I evaluate capital allocation efficiency through earnings per share. This metric divides total annual net income by the number of securities, excluding the impact of issuances. By analyzing the current trailing twelve-month net income per share, an investor determines the real value of the business. For BioCardia, Inc. (BCDA), this indicator reflects the costs of developing cell therapy. Negative values confirm the stage of costly clinical trials.

Perusahaan pesaing